Caris Life Sciences experienced a significant uptick in its stock price, reflecting strong investor confidence.
Caris Life Sciences, Inc. Common Stock (NASDAQ:CAI) went up yesterday by an impressive 8.00%, closing at CA$29.70. This surge highlights the company's robust performance and positive market sentiment.
Advertisement
Caris Life Sciences, Inc. Common Stock
CAI.US
CAI.US
Caris Life Sciences, Inc. Common Stock
WealthAwesomeMarket cap
$8.40B
P/E
17.6x
52W high
$33.65
52W low
$14.19
1W change
+4.95%
Analyst Price Targets
Based on 14 analysts covering CAI · as of Oct 12, 2026
Wall Street analysts forecast CAI stock price to rise 151823.0% over the next 12 months.
Consensus
Buy4.36 / 5.00
Avg. Target
C$30.38
+151823.0% Upside
Previously C$29.08 on Oct 7, 2026
Current Price
C$0.02
Last close
Analyst Breakdown (14 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on CAI's historical volatility
30-Day Vol
69.5%
Annualized
90-Day Vol
72.8%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$35.51
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$31.52 | C$24.80 – C$40.06 |
| 60 trading days | C$33.45 | C$23.84 – C$46.95 |
| 90 trading days | C$35.51 | C$23.44 – C$53.77 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: The recent performance of Caris Life Sciences suggests a growing confidence among investors, particularly in light of its strong revenue growth and future guidance.
8.00% Increase in Stock Price
Advertisement
Caris Life Sciences' stock price rose to CA$29.70, reflecting strong investor sentiment following impressive financial results.
Bull case
Caris Life Sciences reported a remarkable 113% increase in total revenue for Q3 2025, boosting investor confidence and prompting a positive reevaluation of the stock's potential. This growth was mainly driven by the company's molecular profiling services, which are gaining traction in the healthcare market.
Bear case
Despite the recent surge, there are concerns about whether this growth can be sustained in a competitive market and the potential for volatility in future earnings. Investors should remain cautious about these factors as they consider their positions.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
